Found: 2
Select item for more details and to access through your institution.
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand‐1 (PD‐L1) expression and increases anti‐tumour effects of T cells in multiple myeloma.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 3, p. 568, doi. 10.1111/bjh.17282
- By:
- Publication type:
- Article
The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 578, doi. 10.1002/hon.3071
- By:
- Publication type:
- Article